secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2026-06-22T11:09:59+00:00
Accession:  0001193125-26-276693
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TSC-101 Cohort C: 11/14 patients achieved complete donor chimerism; Phase 3 start planned this month
--------------------------------------------------------------------------------

- 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first TSC-101 infusion; 2 additional patients approaching.
- ~90% manufacturing success rate (17/19) with commercial-ready process; 14/19 patients received first infusion.
- One TP53-mutated AML patient remained in complete donor chimerism 6 months post-HCT.
- TSC-101 well-tolerated; safety consistent with Cohort A; company plans to initiate Phase 3 ALLOHA-2 study this month.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312526276693/0001193125-26-276693-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312526276693/d103234d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-276693

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer